Search results for "CLSI"

showing 2 items of 2 documents

EUCAST un CLSI metožu salīdzinājums paplašināta spektra βeta-laktamāžu noteikšanai Enterobacteriaceae dzimtas klīniskajos izolātos

2015

Darba mērķis bija salīdzināt EUCAST un CLSI antimikrobās jutības noteikšanas metodes paplašināta spektra β-laktamāžu noteikšanai Enterobacteriaceae dzimtas klīniskajos izolātos. Darba teorētiskajā daļā tika apskatīti biežākie ESBL producējošie Enterobacteriaceae dzimtas pārstāvji, antibakteriālo līdzekļu un rezistences mehānismu raksturojums. Dati iegūti 2014.-2015. g., strādājot klīniskajā mikrobioloģijas laboratorijā. Identificēti un pētīti 269 baktēriju izolāti. Pēc EUCAST standarta 55 izolātiem mainījās antibiogrammas rezultāti. Ceftazidīmam un cefotaksīmam samazinot antibakteriālā līdzekļa koncentrāciju pēc EUCAST standarta, tie tiek padarīti jutīgāki pret ESBL noteikšanu. Pateicoties …

ESBLEnterobacteriaceaeCLSIEUCASTBioloģija
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct